Article Text

Download PDFPDF

P09.12 Hereditary homozygosity and allelic imbalance of HLA as common immune escape mechanisms in esophageal adenocarcinoma
  1. MA Garcia Marquez1,
  2. M Thelen1,
  3. E Bauer1,
  4. K Wennhold1,
  5. J Lehmann1,
  6. D Keller1,
  7. L Maas1,
  8. M Nicolik1,
  9. J George1,
  10. T Zander1,
  11. W Schroeder1,
  12. P Müller1,
  13. C Bruns1,
  14. R Thomas1,
  15. B Gathof1,
  16. A Quaas1,
  17. AM Hillmer1,
  18. M Peifer1,
  19. M von Bergwelt-Baildon2 and
  20. HA Schlößer1
  1. 1University Clinic of Cologne, Cologne, Germany
  2. 2University Hospital, LMU Munich, Munich, Germany


Background The human leukocyte antigen (HLA) genotype of an individual defines the repertoire of peptides which can be presented to T cells. In the tumor microenvironment, neoantigen presentation can be abrogated by alterations ofHLA class I molecules, which have a direct impact in immune surveillance. This study aims to elucidate the impact of hereditary homozygosity and imbalanced expression of HLA-I loci on the repertoire of immunogenic peptides that are presented in esophago-gastric adenocarcinoma patients (EGA).

Materials and Methods High-resolution clinical-grade HLA-genotyping was performed using the NGS method (n=80). Whole exome sequencing (WES) was done on tumor and blood (n=39) to call for somatic mutations. The amount of potential high affinity binders derived from 10 tumor-associated antigens (TAAs) frequently expressed in EGA and non-synonymous mutations obtained from WES data were determined using an in-silico approach for MHC-binding ( Gene expression profiling was done with 3`RNAseq (n=39). Whole RNAseq data was used to detect imbalanced or loosed expression of HLA-A/B/C alleles (n=19).

Results We compared the frequency of HLA homozygosity in EGA patients to an HLA-matched reference population derived from a large cohort of bone marrow donors (n=7.615). We demonstrate that homozygosity of HLA-I loci is significantly enriched in the germline of EGA patients compared to the control population (35% vs. 19%, corresponding to an odds ratio (OR) for homozygosity of 2.282 (95% CI 1.442–3.615, p<0.001)). We then aimed to estimate the influence of HLA-homozygosity in the context of tumor immune surveillance. Predictions by IEDB analysis resource tool indeed showed a reduced repertoire of high and moderate-affinity MHC-binders (both TAA-derived and mutation-derived peptides) in the homozygous cohort. Our findings demonstrate a reduced amount of potentially immunogenic peptides in EGA patients with HLA-homozygosity for at least one locus, which may result in impaired cancer immunosurveillance. In line with this observation, artificial restoration of the genotype of homozygous patients to a heterozygous genotype, resulted in a set of predicted good-binding peptides of comparable size to the heterozygous cohort. While 35% of EGA patients showed germline homozygosity of HLA-I loci, quantification of allele-specific expression of HLA-I revealed altered expression in 9 out of 12 heterozygous patients (75%). 3 of these patients showed complete loss of heterozygosity, whereas the others had altered expression of one or two HLA-I molecules. The allelic imbalance was significantly higher in heterozygous compared to homozygous were only 2 patients showed altered expression of one HLA-I molecule (28.6%, p=0.0240). None of the patients with allelic imbalance carried genetic mutations associated with HLA-I genes, underlying epigenetic regulation.

Conclusions The high frequency of genomic HLA-I homozygosity observed in the EGA cohort suggests that limitation of neoantigen presentation might have a role during EGA development and may reflect an increased cancer risk for these patients. Moreover, the results herein highlight that despite having a complete set of HLA-I alleles on a genomic level, the majority of EGA patients carry allelic imbalance that limit the repertoire of neoantigens for presentation to immune cells.

Disclosure Information M.A. Garcia Marquez: None. M. Thelen: None. E. Bauer: None. K. Wennhold: None. J. Lehmann: None. D. Keller: None. L. Maas: None. M. Nicolik: None. J. George: None. T. Zander: None. W. Schroeder: None. P. Müller: None. C. Bruns: None. R. Thomas: None. B. Gathof: None. A. Quaas: None. A.M. Hillmer: None. M. Peifer: None. M. von Bergwelt-Baildon: C. Other Research Support (supplies, equipment, receipt of drugs or other in-kind support); Significant; Astellas, Roche, MSD. D. Speakers Bureau/Honoraria (speakers bureau, symposia, and expert witness); Significant; BMS. H.A. Schlößer: B. Research Grant (principal investigator, collaborator or consultant and pending grants as well as grants already received); Significant; Astra Zeneca.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.